Approval reinforces Myriad’s leadership in comprehensive HRD testing and establishes MyChoice CDx as the only FDA-approved companion diagnostic for Zejula in the United States SALT LAKE CITY, March 17 ...
SALT LAKE CITY, Utah, May 30, 2014 – Myriad Genetics, Inc. (NASDAQ: MYGN), a global leader in molecular diagnostics, announced the presentation of new data at the American Society of Clinical Oncology ...
SALT LAKE CITY, Sept. 05, 2017 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics and personalized medicine, announced today that it has launched riskScore ™, a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results